Annual Report 2012 Active Biotech AB (publ)

Annual Report 2012 Active Biotech AB (publ) 
LUND, SWEDEN -- (Marketwired) -- 04/15/13 --  Active Biotech's Annual
Report 2012 (in Swedish) is now available for download at The English version will be available within
The Annual Report will only be digitally distributed. 
Lund, April 15, 2013 
Active Biotech AB (publ) 
Tomas Leanderson President & CEO 
Active  Biotech AB  (NASDAQ OMX  NORDIC: ACTI)  is a  biotechnology
company with
focus  on autoimmune/inflammatory diseases and cancer.
Projects in pivotal phase
are   laquinimod,   an   orally  
administered   small   molecule   with unique
properties for the treatment of multiple sclerosis, tasquinimod
prostate cancer and ANYARA primarily for the treatment of renal cell
In  addition, laquinimod is in  Phase II development for 
Crohn's and Lupus. The company  also has  one additional  project in 
clinical development,  the orally
administered    compound    57-57
for    Systemic    Sclerosis.   Please visit
for more information. 
Active Biotech AB (Corp. Reg. No. 556223-9227) 
Box 724, SE-220 07 Lund 
Tel: +46 46 19 20 00 
Fax: +46 46 19 11 00 
Active Biotech is required under the Financial Instruments Trading
Act to make
the information in this press release public. The
information was submitted for
publication at 10:00 a.m. CET on April
15, 2013. 
Annual Report 2012 Active Biotech AB (publ): 
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants
(i) the releases contained herein are protected by copyright and    
other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and     
originality of the information contained therein. 
Source: Active Biotech via Thomson Reuters ONE 
For further information, please contact:
Hans Kolam
Tel +46 (0)46 19 20 44
Press spacebar to pause and continue. Press esc to stop.